CDT EquityCDT -10.81%10 9-Day RSI is 38.00 as of Jun. 29, 2026. GuruFocus rates CDT with a GF Score™ of 10/100. The stock has 5 warning signs investors should review. Among 1,422 Biotechnology companies, CDT Equity ranks better than 66.74% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-06-29), CDT Equity's 9-Day RSI is 38.00.
The industry rank for CDT Equity's 9-Day RSI or its related term are showing as below:
CDT's 9-Day RSI is ranked better than 66.74% of 1422
companies
in the Biotechnology industry
Industry Median: 45.77
vs CDT: 38.00
CDT Equity (NAS:CDT) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
CDT Equity 9-Day RSI Related Terms
CDT vs CLDI, DCOY, ACUT: 9-Day RSI Comparison
For the Biotechnology subindustry, CDT Equity's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CDT Equity 9-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CDT Equity's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where CDT Equity's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CDT Equity (CDT) has a 9-Day RSI of 38.00 as of Jun. 29, 2026. According to the industry distribution chart, CDT Equity ranks #473 out of 1422 companies in the Biotechnology industry, placing it in the top 33.3%.
Is CDT Equity's 9-Day RSI too high?
CDT Equity's current 9-Day RSI is 38.00. The Biotechnology industry median 9-Day RSI is 45.77. CDT Equity's value of 38.00 is 17% below this industry median. Based on the distribution chart, CDT Equity ranks #473 out of 1422 companies in the Biotechnology industry, which is above the industry midpoint. Overall, CDT Equity has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does CDT Equity's 9-Day RSI compare to CLDI and DCOY?
According to the Biotechnology industry distribution chart, CDT Equity ranks #473 out of 1422 companies for 9-Day RSI. This puts CDT Equity in the upper half of its industry. The industry median 9-Day RSI is 45.77. CDT Equity's value of 38.00 is 17% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Biotechnology company?
The median 9-Day RSI among Biotechnology companies is 45.77, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CDT Equity's current 9-Day RSI of 38.00 is 17% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median 9-Day RSI is 45.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CDT Equity's current 9-Day RSI is 38.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CDT Equity stock overvalued right now?
CDT Equity (CDT) has a current 9-Day RSI of 38.00. The current 9-Day RSI is 38.00 and 17% below the Biotechnology industry median of 45.77. CDT Equity's overall GF Score™ is 10/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For CDT Equity (CDT), the current 9-Day RSI is 38.00 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CDT Equity Inc is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. It has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. The company's pipeline includes candidates that target autoimmune disorders, as well as idiopathic male infertility, oncology, dermatology, rare disease and animal health. It has one operating segment focused on the research and development of clinical assets.
10GF Score
Get the complete analysis for CDT
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CDT has been successfully added to your 